- Home
- LGVN vs ADXN Comparison
LGVN vs ADXN Comparison
Compare LGVN & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LGVN | ADXN |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9M | 10.3M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LGVN | ADXN |
|---|---|---|
| Price | $0.58 | $7.21 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.50 | N/A |
| AVG Volume (30 Days) | ★ 143.0K | 2.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $709,000.00 | N/A |
| Revenue This Year | N/A | $86.57 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.49 | $6.51 |
| 52 Week High | $1.92 | $12.05 |
Technical Indicators
Market Signals| Indicator | LGVN | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | 52.96 | 42.09 |
| Support Level | $0.52 | $7.32 |
| Resistance Level | $0.57 | $8.00 |
| Average True Range (ATR) | 0.03 | 0.29 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 96.44 | 39.49 |
Price Performance
Historical ComparisonAbout LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.